Benzinga | Oct 14, 2020 05:03PM EDT

Iovance Biotherapeutics Reports Will Present Clinical Data In Head And Neck Cancer At Society For Immunotherapy Of Cancer Meeting Nov. 9-14

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new interim clinical data for the tumor infiltrating lymphocyte (TIL) therapy LN-145 in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC) will be presented at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The SITC 35th Annual Meeting will be held virtually from November 9-14, 2020. Details of the poster are as follows:

Title Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

Authors A Jimeno, et al.